InkVivo raises €1.2M Pre-Seed round
13 August 2025· Lugano, Switzerland· health, biotech, drug_delivery, materials, manufacturing, b2b, software_hardware
The funding will be used to advance the company's clinical development of its polymer-based drug delivery formulations, broaden its product pipeline across therapeutic areas (initially gastroretentive systems for anemia and obesity, expanding to nutraceuticals, oncology, and metabolic disorders like Type 2 diabetes), expand R&D efforts, and accelerate strategic partnerships with pharmaceutical and nutraceutical companies.
Investors
LeadTiVentures
Also participating
angel investorsClaves Investments
About InkVivo
Stage
Pre-Seed
Headquarters
Lugano, Switzerland
Founded
2020
Team Size
6–20
Sectors
healthbiotechdrug_deliverymaterialsmanufacturingb2bsoftware_hardware